| Year |
Citation |
Score |
| 2024 |
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, et al. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. Jco Precision Oncology. 8: e2300454. PMID 38591867 DOI: 10.1200/PO.23.00454 |
0.332 |
|
| 2023 |
Sivapalan L, Iams WT, Belcaid Z, Scott SC, Niknafs N, Balan A, White JR, Kopparapu P, Cann C, Landon BV, Pereira G, Velculescu VE, Hann CL, Lovly CM, Anagnostou V. Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF14. PMID 37071497 DOI: 10.1158/1078-0432.CCR-22-2242 |
0.31 |
|
| 2023 |
Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Translational Lung Cancer Research. 12: 615-628. PMID 37057106 DOI: 10.21037/tlcr-22-708 |
0.421 |
|
| 2023 |
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, ... ... Lovly CM, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 340-350. PMID 37015337 DOI: 10.6004/jnccn.2023.0020 |
0.334 |
|
| 2022 |
Lin HM, Wu Y, Yin Y, Niu H, Curran EA, Lovly CM, Humphries MJ. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clinical Lung Cancer. PMID 36376172 DOI: 10.1016/j.cllc.2022.09.010 |
0.382 |
|
| 2022 |
Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, et al. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Science Signaling. 15: eabj5879. PMID 35973030 DOI: 10.1126/scisignal.abj5879 |
0.343 |
|
| 2022 |
Sato H, Kubota D, Qiao H, Jungbluth A, Rekhtman N, Schoenfeld AJ, Yu HA, Riely GJ, Toyooka S, Lovly CM, Paik P, Ladanyi M, Fan PD. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. Jco Precision Oncology. 6: e2200088. PMID 35952318 DOI: 10.1200/PO.22.00088 |
0.351 |
|
| 2022 |
Brown BP, Zhang YK, Kim S, Finneran P, Yan Y, Du Z, Kim J, Hartzler AL, LeNoue-Newton ML, Smith AW, Meiler J, Lovly CM. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 119: e2206588119. PMID 35867821 DOI: 10.1073/pnas.2206588119 |
0.324 |
|
| 2022 |
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, ... ... Lovly CM, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 497-530. PMID 35545176 DOI: 10.6004/jnccn.2022.0025 |
0.362 |
|
| 2021 |
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, ... ... Lovly CM, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 254-266. PMID 33668021 DOI: 10.6004/jnccn.2021.0013 |
0.311 |
|
| 2021 |
Du Z, Brown BP, Kim S, Ferguson D, Pavlick DC, Jayakumaran G, Benayed R, Gallant JN, Zhang YK, Yan Y, Red-Brewer M, Ali SM, Schrock AB, Zehir A, Ladanyi M, ... ... Lovly CM, et al. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nature Communications. 12: 1382. PMID 33654076 DOI: 10.1038/s41467-021-21613-6 |
0.356 |
|
| 2020 |
Buck JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Noor Tantawy M, Charles Manning H. N-[F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer. Bioorganic & Medicinal Chemistry Letters. 30: 127257. PMID 32631505 DOI: 10.1016/J.Bmcl.2020.127257 |
0.401 |
|
| 2020 |
Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong HS, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. Embo Molecular Medicine. e11099. PMID 32558295 DOI: 10.15252/Emmm.201911099 |
0.452 |
|
| 2020 |
Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL. COVID-19 and immune checkpoint inhibitors: initial considerations. Journal For Immunotherapy of Cancer. 8. PMID 32434790 DOI: 10.1136/Jitc-2020-000933 |
0.355 |
|
| 2020 |
Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, et al. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clinical Lung Cancer. PMID 32201247 DOI: 10.1016/J.Cllc.2020.02.008 |
0.41 |
|
| 2020 |
Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS, Hershberger PA. Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. Cancers. 12. PMID 32183160 DOI: 10.3390/Cancers12030675 |
0.382 |
|
| 2020 |
Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, ... ... Lovly C, et al. New approaches to small cell lung cancer therapy : from the laboratory to the clinic. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32018053 DOI: 10.1016/J.Jtho.2020.01.016 |
0.446 |
|
| 2020 |
Sato H, Kubota D, Paik PK, Qiao H, Jungbluth AA, Rekhtman N, Schoenfeld AJ, Yu HA, Riely GJ, Lovly CM, Ladanyi M, Fan P. YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E21591 |
0.452 |
|
| 2020 |
Brown BP, Mendenhall J, Lovly C, Meiler J. Abstract 22: Toward automated design of mutant-selective tyrosine kinase inhibitors using dynamic pharmacophore mapping and machine learning Clinical Cancer Research. 26: 22-22. DOI: 10.1158/1557-3265.Advprecmed20-22 |
0.411 |
|
| 2020 |
Smith JT, Balar A, Lakhani DA, Kluwe C, Zhao Z, Kopparapu P, Almodovar K, Muterspaugh A, Yan Y, York S, Horn L, Antic S, Bertucci C, Shaffer T, Hodsdon L, ... ... Lovly C, et al. Abstract 715: Circulating tumor DNA as a potential biomarker of radiographic tumor burden in small cell lung cancer Clinical Trials. DOI: 10.1158/1538-7445.Am2020-715 |
0.38 |
|
| 2020 |
Thomas PL, Betts C, Gonzalez G, Coussens LM, Lovly CM. Abstract 3862: Defining immune contexture in small cell lung cancer: Implications for immunotherapy Cancer Research. 80: 3862-3862. DOI: 10.1158/1538-7445.Am2020-3862 |
0.371 |
|
| 2020 |
Remsing Rix L, Sumi N, Bryant A, Desai B, Li X, Welsh E, Fang B, Kuenzi B, Antonia S, Lovly C, Koomen J, Marusyk A, Haura E, Rix U. B40 IGF-Binding Protein-Mediated Sensitization of EGFR-Mutant NSCLC Cells to Osimertinib by Cancer-Associated Fibroblast Journal of Thoracic Oncology. 15: S38. DOI: 10.1016/J.Jtho.2019.12.104 |
0.418 |
|
| 2019 |
Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Du L, Hernandez J, Huang V, Waqar SN, Patel S, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, ... ... Lovly CM, et al. Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii48. PMID 32131242 DOI: 10.1093/Annonc/Mdz063.010 |
0.438 |
|
| 2019 |
Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, ... ... Lovly CM, et al. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. The Oncologist. PMID 31604903 DOI: 10.1634/Theoncologist.2018-0528 |
0.42 |
|
| 2019 |
Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, ... ... Lovly CM, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31446141 DOI: 10.1016/J.Jtho.2019.08.003 |
0.505 |
|
| 2019 |
Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux J, Vaupel C, Boyd KL, Summitt IB, Wang LL, Schneider JT, Warner JL, Zhao Z, Lovly CM. Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31201935 DOI: 10.1016/J.Jtho.2019.05.042 |
0.405 |
|
| 2019 |
Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V. Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Cell Systems. PMID 30797775 DOI: 10.1016/J.Cels.2019.01.003 |
0.398 |
|
| 2019 |
Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali SM, Bazhenova L, Schrock AB, Meiler J, Lovly CM. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30796031 DOI: 10.1158/1078-0432.Ccr-18-3829 |
0.468 |
|
| 2019 |
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, ... Lovly CM, et al. Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. 9: 303. PMID 30737217 DOI: 10.1158/2159-8290.Cd-18-1515 |
0.376 |
|
| 2019 |
Tsou TC, Gowen K, Ali SM, Miller VA, Schrock AB, Lovly CM, Reckamp KL. Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 14: e29-e30. PMID 30683295 DOI: 10.1016/J.Jtho.2018.10.169 |
0.361 |
|
| 2019 |
Riely GJ, Lovly CM, Messina CG, Bienert S, Alexander K, Pao W, Baxi S, Doebele RC. Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. Journal of Clinical Oncology. 37: 9062-9062. DOI: 10.1200/Jco.2019.37.15_Suppl.9062 |
0.432 |
|
| 2019 |
Westover D, Zhang Y, Yan Y, Himmelberg S, Tyson DR, Bauer JA, Lovly CM. Abstract 330: High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance Cancer Research. 79: 330-330. DOI: 10.1158/1538-7445.Sabcs18-330 |
0.443 |
|
| 2019 |
Huang V, Yan Y, Qiao H, Zhang Y, Lovly CM. Abstract 316: Parallel activation of MEK as a mechanism of resistance to ALK inhibitor therapy Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-316 |
0.342 |
|
| 2019 |
Zhang Y, Brown BP, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. Abstract 930: On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation Cancer Research. 79: 930-930. DOI: 10.1158/1538-7445.Am2019-930 |
0.487 |
|
| 2019 |
Du Z, Gallant J, Red-Brewer M, Brown B, Sheehan J, Meiler J, Lovly CM. Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization Cancer Research. 79: 867-867. DOI: 10.1158/1538-7445.Am2019-867 |
0.451 |
|
| 2019 |
Paliouras AR, Magee P, Sahoo S, Leong HS, Krebs M, Blackhall F, Lovly CM, Garofalo M. Abstract 4761: Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors Cancer Research. 79: 4761-4761. DOI: 10.1158/1538-7445.Am2019-4761 |
0.455 |
|
| 2019 |
Rix LLR, Sumi NJ, Bryant AT, Li X, Welsh EA, Fang B, Kuenzi BM, Antonia SJ, Marusyk A, Lovly CM, Koomen JM, Haura EB, Rix U. Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C110 |
0.5 |
|
| 2019 |
Riely G, Lovly C, Messina C, Bienert S, Alexander K, Pao W, Magee K, Baxi S, Doebele R. P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.740 |
0.393 |
|
| 2019 |
Malik S, Hu C, Shaw A, Korn E, Tsao A, Doebele R, Stinchcombe T, Lovly C, Bradley J. P2.01-04 NCI-NRG Oncology ALK PROTOCOL (NRG-LU003): A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1348 |
0.34 |
|
| 2019 |
Jain N, Micheel C, Balko J, Lovly C, Park B. 45. Molecular tumor board efforts at Vanderbilt-Ingram Cancer Center Cancer Genetics and Cytogenetics. DOI: 10.1016/J.Cancergen.2019.04.051 |
0.339 |
|
| 2018 |
Iams WT, Beckermann KE, Almodovar K, Hernandez J, Vnencak-Jones C, Lim LP, Raymond CK, Horn L, Lovly CM. Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS mutant lung adenocarcinoma: A report of two cases. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30543839 DOI: 10.1016/J.Jtho.2018.11.031 |
0.414 |
|
| 2018 |
Childress MA, Himmelberg SM, Chen H, Deng W, Davies MA, Lovly CM. ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Molecular Cancer Research : McR. PMID 30002191 DOI: 10.1158/1541-7786.Mcr-18-0171 |
0.426 |
|
| 2018 |
Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, ... ... Lovly CM, et al. amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. PMID 29875142 DOI: 10.1073/Pnas.1717782115 |
0.487 |
|
| 2018 |
Horn L, Infante JR, Reckamp KL, Blumenshein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, ... ... Lovly CM, et al. Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563138 DOI: 10.1158/1078-0432.Ccr-17-2398 |
0.437 |
|
| 2018 |
Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: i10-i19. PMID 29462254 DOI: 10.1093/Annonc/Mdx703 |
0.506 |
|
| 2018 |
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer. 17: 58. PMID 29455648 DOI: 10.1186/S12943-018-0782-4 |
0.418 |
|
| 2018 |
Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, ... Lovly CM, et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017762294. PMID 29373100 DOI: 10.1200/Jco.2017.76.2294 |
0.475 |
|
| 2018 |
Gallant JN, Lovly CM. Established, emerging, and elusive molecular targets in the treatment of lung cancer. The Journal of Pathology. PMID 29344953 DOI: 10.1002/Path.5038 |
0.419 |
|
| 2018 |
Iams WT, Almodovar K, Meador C, Zhao Z, York S, Horn L, Raymond C, Hernandez J, Lim L, Lovly CM. Clinical implications of cell free DNA concentration in patients with small cell lung cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E20563 |
0.406 |
|
| 2018 |
Freeman-Daily J, Goldman L, Tomalia T, Lovly CM, Patel MI, Shaw AT, Addario BJ, Walia G, Young SW, Doebele RC. Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data Cancer Research. 78: 4766-4766. DOI: 10.1158/1538-7445.Am2018-4766 |
0.431 |
|
| 2018 |
Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux J, Vaupel C, Wang LL, Schneider JT, Warner JL, Zhao Z, Lovly CM. Abstract 1025: Clinical outcomes and differential tumor immune microenvironment in patients with small cell lung cancer and paraneoplastic syndromes Cancer Research. 78: 1025-1025. DOI: 10.1158/1538-7445.Am2018-1025 |
0.34 |
|
| 2017 |
Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell & Melanoma Research. PMID 29171936 DOI: 10.1111/Pcmr.12674 |
0.42 |
|
| 2017 |
Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM. Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28951314 DOI: 10.1016/J.Jtho.2017.09.1951 |
0.41 |
|
| 2017 |
Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SI, Raez LE. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. Lung Cancer (Amsterdam, Netherlands). 111: 84-87. PMID 28838405 DOI: 10.1016/J.Lungcan.2017.07.002 |
0.518 |
|
| 2017 |
Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer (Amsterdam, Netherlands). 111: 61-64. PMID 28838400 DOI: 10.1016/J.Lungcan.2017.07.006 |
0.498 |
|
| 2017 |
Lovly CM, Iyengar P, Gainor JF. Managing Resistance to EFGR- and ALK-Targeted Therapies. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 37: 607-618. PMID 28561721 DOI: 10.14694/EDBK_176251 |
0.362 |
|
| 2017 |
Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, De Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Research. PMID 28416483 DOI: 10.1158/0008-5472.Can-16-2300 |
0.522 |
|
| 2017 |
Hanker AB, Red Brewer M, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, ... Lovly CM, et al. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. PMID 28274957 DOI: 10.1158/2159-8290.Cd-16-1431 |
0.422 |
|
| 2017 |
Ganesan S, Bhanot G, Mehnert JM, Silk AW, Ross JS, Pavlick D, Ali SM, Markowski P, Kaufman HL, Sullivan RJ, Lovly CM, Sosman JA, Johnson DB, Betigeri A, Subramanian K, et al. Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. Journal of Clinical Oncology. 35: 35-35. DOI: 10.1200/Jco.2017.35.7_Suppl.35 |
0.434 |
|
| 2017 |
Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, Germer S, Jordan E, Wang L, Jungbluth AA, Spraggon L, Lovly CM, Kris MG, Yu HA, Riely GJ, et al. YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. Journal of Clinical Oncology. 35: 9043-9043. DOI: 10.1200/Jco.2017.35.15_Suppl.9043 |
0.485 |
|
| 2017 |
Ou SI, Schrock AB, Gowen K, Stephens PJ, Ross JS, Johnson ML, Lovly CM, Ali SM, Miller VA, Shaw AT. Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: 9010-9010. DOI: 10.1200/Jco.2017.35.15_Suppl.9010 |
0.416 |
|
| 2017 |
Iams WT, Almodovar K, Meador C, York SJ, Horn L, Raymond C, Hernandez J, Shaffer T, DiPasquo D, Lim L, Lovly CM. Longitudinal monitoring of circulating tumor DNA and peripheral T cell repertoire in patients with small cell lung cancer. Journal of Clinical Oncology. 35: 8571-8571. DOI: 10.1200/Jco.2017.35.15_Suppl.8571 |
0.43 |
|
| 2017 |
Hanker A, Brewer MR, Sheehan J, Koch J, Lanman R, Hyman D, Cutler R, Lalani A, Cross D, Lovly C, Meiler J, Arteaga C. Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-03 |
0.377 |
|
| 2017 |
Lovly CM, Almodovar K, Iams WT, Meador CB, York S, Horn L, Raymond CK, Hernandez J, Lim LP. Abstract 4949: Longitudinal monitoring of cell-free DNA in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse Cancer Research. 77: 4949-4949. DOI: 10.1158/1538-7445.Am2017-4949 |
0.396 |
|
| 2017 |
Westover D, Meador CB, Ichihara E, Byrd HF, Eberlein C, Yan Y, Cross DA, Lovly CM. Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models ofEGFR-mutant cancer Cancer Research. 77: 3160-3160. DOI: 10.1158/1538-7445.Am2017-3160 |
0.364 |
|
| 2017 |
Ikeda S, Gay L, Pavlick D, Chung J, Ramkissoon S, Daniel S, Elvin J, Severson E, Bivona T, Reckamp K, Klempner S, Ou S, Schrock A, Miller V, Stephens P, ... ... Lovly C, et al. Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types Annals of Oncology. 28: x1. DOI: 10.1093/Annonc/Mdx652 |
0.398 |
|
| 2017 |
Gay L, Pavlick D, Chung J, Ramkissoon S, Daniel S, Elvin J, Severson E, Bivona T, Reckamp K, Klempner S, Ou S, Schrock A, Miller V, Stephens P, Ross J, ... ... Lovly C, et al. Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types Annals of Oncology. 28: v595. DOI: 10.1093/Annonc/Mdx391 |
0.39 |
|
| 2017 |
Schneider J, Jain P, Schalper K, Lovly C, Gardner F, Ross J, Schrock A, Ali S, Miller V, Velcheti V. MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.588 |
0.437 |
|
| 2017 |
Westover D, Qiao H, Ichihara E, Meador CB, Lovly CM. Mechanisms of Osimertinib Resistance in EGFR Mutant Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.06.063 |
0.465 |
|
| 2017 |
Du Z, Gallant J, Sheehan J, Meiler J, Lovly C. Intramolecular Dimerization of EGFR Kinase Domain Duplication as a Novel Activation Mechanism Journal of Thoracic Oncology. 12: S1536. DOI: 10.1016/J.Jtho.2017.06.022 |
0.375 |
|
| 2017 |
Gadgeel S, Johnson A, Horn L, Lovly C, Riess J, Campregher P, Stephens P, Ross J, Miller V, Cruz M, Ali S, Schrock A. P3.02c-024 Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling: Topic: Targeted Therapy Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1819 |
0.324 |
|
| 2016 |
Qiao H, Lovly CM. Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. Cancer Discovery. 6: 1084-1086. PMID 27698100 DOI: 10.1158/2159-8290.Cd-16-0910 |
0.48 |
|
| 2016 |
Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S209-S210. PMID 27676529 DOI: 10.1016/J.Jtho.2016.08.066 |
0.351 |
|
| 2016 |
Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S176-S177. PMID 27676483 DOI: 10.1016/J.Jtho.2016.08.017 |
0.319 |
|
| 2016 |
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, ... ... Lovly CM, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunology Research. PMID 27671167 DOI: 10.1158/2326-6066.Cir-16-0143 |
0.333 |
|
| 2016 |
Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology. Bmc Medicine. 14: 110. PMID 27469586 DOI: 10.1186/S12916-016-0654-Y |
0.399 |
|
| 2016 |
Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA. Melanoma driver mutations and immune therapy. Oncoimmunology. 5: e1051299. PMID 27467925 DOI: 10.1080/2162402X.2015.1051299 |
0.358 |
|
| 2016 |
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen I, Scheel A, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27252416 DOI: 10.1158/1078-0432.Ccr-15-1915 |
0.46 |
|
| 2016 |
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, ... ... Lovly CM, et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discovery. PMID 27102076 DOI: 10.1158/2159-8290.Cd-16-0075 |
0.494 |
|
| 2016 |
Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM. The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome. Translational Oncology. 9: 163-5. PMID 27084433 DOI: 10.1016/J.Tranon.2016.03.001 |
0.361 |
|
| 2016 |
Giuse NB, Kusnoor SV, Koonce TY, Naylor HM, Chen SC, Blasingame MN, Anderson IA, Micheel CM, Levy MA, Ye F, Lovly CM. Guiding Oncology Patients Through the Maze of Precision Medicine. Journal of Health Communication. 21: 5-17. PMID 27043753 DOI: 10.1080/10810730.2015.1131772 |
0.3 |
|
| 2016 |
Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. Lung Cancer (Amsterdam, Netherlands). 92: 29-34. PMID 26775593 DOI: 10.1016/J.Lungcan.2015.11.004 |
0.454 |
|
| 2016 |
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. PMID 26744526 DOI: 10.1158/0008-5472.Can-15-0717 |
0.522 |
|
| 2016 |
Horn L, Wakelee HA, Reckamp KL, Blumenschein GR, Infante JR, Carter CA, Waqar SN, Neal JW, Gockerman JP, Harrow K, Dukart G, Liang C, Gibbons JJ, Hernandez J, Newman-Eerkes T, ... ... Lovly CM, et al. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9056-9056. DOI: 10.1200/Jco.2016.34.15_Suppl.9056 |
0.465 |
|
| 2016 |
Frampton GM, Fabrizio D, Chalmers ZR, Ross JS, Johnson DB, Lovly CM, Sosman JA, Miller VA, Stephens P. Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling. Journal of Clinical Oncology. 34: 11558-11558. DOI: 10.1200/Jco.2016.34.15_Suppl.11558 |
0.39 |
|
| 2016 |
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Ennis R, Fabrizio D, Greenbowe JR, Ali SM, Frederick DT, Puzanov I, Balko JM, Cates J, Ross JS, Robins H, Miller VA, ... ... Lovly CM, et al. Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. Journal of Clinical Oncology. 34: 105-105. DOI: 10.1200/Jco.2016.34.15_Suppl.105 |
0.351 |
|
| 2016 |
Lovly CM, Infante JR, Blumenschein GR, Reckamp K, Wakelee H, Carter CA, Waqar SN, Neal J, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Horn L. Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct088 |
0.388 |
|
| 2016 |
Qiao H, Yan Y, Smith MA, Haura EB, Ladanyi M, Lovly CM. Abstract 311: Novel role for MIG-6 in mediating TKI resistance inALK-rearranged lung cancer Cancer Research. 76: 311-311. DOI: 10.1158/1538-7445.Am2016-311 |
0.536 |
|
| 2016 |
Horn L, Wakelee H, Blumenschein G, Reckamp K, Waqar S, Carter C, Gitlitz B, Infante J, Sanborn R, Neal J, Gockerman J, Dukart G, Harrow K, Liang C, Gibbons J, ... ... Lovly C, et al. Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx) Annals of Oncology. 27: vi419. DOI: 10.1093/Annonc/Mdw383.10 |
0.401 |
|
| 2016 |
Reckamp KL, Infante JR, Blumenschein GR, Wakelee H, Carter CA, Gockerman JP, Lovly C, Dukart G, Harrow K, Liang C, Gibbons JJ, Horn L. Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology. 11. DOI: 10.1016/J.Jtho.2015.12.062 |
0.384 |
|
| 2016 |
Almodovar-Garcia K, Yan Y, Wang Y, Zhao Z, Guo X, Xu Y, Lovly CM. A novel patient-derived cell line originated at the time of crizotinib resistance displays a mesenchymal phenotype Journal of Thoracic Oncology. 11. DOI: 10.1016/J.Jtho.2015.12.028 |
0.32 |
|
| 2015 |
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, et al. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26438117 DOI: 10.1200/Jco.2015.62.0138 |
0.409 |
|
| 2015 |
Iams WT, Lovly CM. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4270-7. PMID 26429980 DOI: 10.1158/1078-0432.Ccr-14-2518 |
0.43 |
|
| 2015 |
Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass.). 21: 378-82. PMID 26389762 DOI: 10.1097/Ppo.0000000000000142 |
0.506 |
|
| 2015 |
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, ... ... Lovly CM, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nature Medicine. 21: 1038-47. PMID 26301689 DOI: 10.1038/Nm.3930 |
0.407 |
|
| 2015 |
Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discovery. PMID 26286086 DOI: 10.1158/2159-8290.Cd-15-0654 |
0.509 |
|
| 2015 |
Ichihara E, Lovly CM. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Cancer Discovery. 5: 694-6. PMID 26152920 DOI: 10.1158/2159-8290.Cd-15-0616 |
0.472 |
|
| 2015 |
Meador CB, Lovly CM. Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Nature Medicine. 21: 663-5. PMID 26151324 DOI: 10.1038/Nm.3899 |
0.408 |
|
| 2015 |
Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e165-73. PMID 25993168 DOI: 10.14694/EdBook_AM.2015.35.e165 |
0.386 |
|
| 2015 |
Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2227-35. PMID 25979929 DOI: 10.1158/1078-0432.Ccr-14-2791 |
0.522 |
|
| 2015 |
Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunology Research. 3: 288-95. PMID 25736262 DOI: 10.1158/2326-6066.Cir-14-0207 |
0.36 |
|
| 2015 |
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, ... Lovly CM, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Molecular Cancer Therapeutics. 14: 542-52. PMID 25477325 DOI: 10.1158/1535-7163.Mct-14-0723 |
0.484 |
|
| 2015 |
Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 431-7. PMID 25415430 DOI: 10.1097/Jto.0000000000000432 |
0.468 |
|
| 2015 |
Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1935-43. PMID 25351745 DOI: 10.1158/1078-0432.Ccr-14-2124 |
0.453 |
|
| 2015 |
Rioth MJ, Staggs D, Hackett L, Sberna T, Lovly CM, Levy MA, Warner J. Distributing genomic data for cancer discovery. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E12544 |
0.32 |
|
| 2015 |
Kris MG, Johnson BE, Kwiatkowski DJ, Wistuba II, Berry LD, Haura EB, Socinski MA, Ramalingam SS, Glisson BS, Waqar SN, Otterson GA, Schiller JH, Garon EB, Cetnar JP, Politi KA, ... ... Lovly CM, et al. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). Journal of Clinical Oncology. 33: 8094-8094. DOI: 10.1200/Jco.2015.33.15_Suppl.8094 |
0.456 |
|
| 2015 |
Ichihara E, Bauer JA, Lu P, Ye F, Cross D, Pao W, Lovly CM. Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma Cancer Research. 75: 768-768. DOI: 10.1158/1538-7445.Am2015-768 |
0.484 |
|
| 2015 |
Ortiz-Cuarán S, Fernandez-Cuesta L, Lovly CM, Bos M, Scheffler M, Michels S, Albus K, Meyer L, König K, Dahmen I, Mueller C, Ozretić L, Tharun L, Schaub P, Florin A, et al. Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas Cancer Research. 75: 752-752. DOI: 10.1158/1538-7445.Am2015-752 |
0.506 |
|
| 2014 |
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, et al. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1629-49. PMID 25361808 DOI: 10.6004/Jnccn.2014.0161 |
0.359 |
|
| 2014 |
Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5898-907. PMID 25303979 DOI: 10.1158/1078-0432.Ccr-13-2437 |
0.489 |
|
| 2014 |
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nature Medicine. 20: 1027-34. PMID 25173427 DOI: 10.1038/Nm.3667 |
0.398 |
|
| 2014 |
Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discovery. 4: 889-95. PMID 24875859 DOI: 10.1158/2159-8290.Cd-14-0377 |
0.4 |
|
| 2014 |
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The Oncologist. 19: 616-22. PMID 24797823 DOI: 10.1200/Jco.2014.32.15_Suppl.11089 |
0.362 |
|
| 2014 |
Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2249-56. PMID 24789032 DOI: 10.1158/1078-0432.Ccr-13-1610 |
0.468 |
|
| 2014 |
Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidel D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, ... ... Lovly CM, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications. 5: 3518. PMID 24670920 DOI: 10.1038/Ncomms4518 |
0.381 |
|
| 2014 |
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2264-75. PMID 24599935 DOI: 10.1158/1078-0432.Ccr-13-1591 |
0.382 |
|
| 2014 |
Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 6-11; quiz 11. PMID 24453288 DOI: 10.6004/Jnccn.2014.0002 |
0.446 |
|
| 2014 |
Horn L, Infante JR, Blumenschein GR, Wakelee HA, Arkenau H, Dukart G, Liang C, Harrow K, Gibbons J, Lovly CM, Pao W. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 8030-8030. DOI: 10.1200/Jco.2014.32.15_Suppl.8030 |
0.413 |
|
| 2014 |
Ortiz-Cuarán S, Fernandez-Cuesta L, Bos M, Heukamp L, Lovly CM, Peifer M, Gardizi M, Scheffler M, Dahmen I, Müller C, König K, Albus K, Florin A, Ansén S, Buettner R, et al. Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas Cancer Research. 74: 956-956. DOI: 10.1158/1538-7445.Am2014-956 |
0.514 |
|
| 2014 |
Vaishnavi A, Le AT, Keysar SB, Lovly CM, Kako S, Varella-Garcia M, Jimeno A, Doebele RC. Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer Cancer Research. 74: 5255-5255. DOI: 10.1158/1538-7445.Am2014-5255 |
0.515 |
|
| 2014 |
Iams WT, Johnson DB, Flavin M, Panageas K, Ayers GD, Zhao Z, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA, Lovly CM. Abstract 2942: NRAS mutation as a predictor of response to immune-based therapies in patients with metastatic melanoma Cancer Research. 74: 2942-2942. DOI: 10.1158/1538-7445.Am2014-2942 |
0.374 |
|
| 2014 |
Horn L, Blumenscheine G, Wakelee HA, Arkenau TH, Dukart G, Harrow K, Liang C, Gibbons JJ, Lovly CM, Infante JR. A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.251 |
0.331 |
|
| 2014 |
Iams WT, Hames ML, Chen H, Aston JL, Horn L, Lovly CM. Prognostic Implications of KRAS Mutation Status and KRAS Mutation Type in Patients With Advanced NSCLC Treated With Cytotoxic Chemotherapy International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.225 |
0.391 |
|
| 2013 |
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discovery. 3: 430-43. PMID 23533265 DOI: 10.1158/2159-8290.Cd-12-0440 |
0.536 |
|
| 2013 |
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.Ccr-12-3173 |
0.47 |
|
| 2013 |
Johnson DB, Lovly CM, Flavin M, Ayers GD, Zhao Z, Iams WT, Iafrate AJ, Berry EG, Terry CR, Sullivan RJ, Carvajal RD, Sosman JA. NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). Journal of Clinical Oncology. 31: 9019-9019. DOI: 10.1200/Jco.2013.31.15_Suppl.9019 |
0.351 |
|
| 2013 |
Lovly CM, Lipson D, Otto G, Brennan T, Sankar S, Stephens PJ, Miller VA, Coffin CM. Potentially actionable kinase fusions in inflammatory myofibroblastic tumors. Journal of Clinical Oncology. 31: 10513-10513. DOI: 10.1200/Jco.2013.31.15_Suppl.10513 |
0.382 |
|
| 2012 |
Horn L, Lovly C. Update on HER1–3 in Advanced Non–Small-Cell Lung Cancer Journal of Thoracic Oncology. 7. PMID 23160321 DOI: 10.1097/Jto.0B013E31826Defaa |
0.416 |
|
| 2012 |
Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Research. 22: 2101-8. PMID 23019146 DOI: 10.1101/Gr.131128.111 |
0.403 |
|
| 2012 |
Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4682-90. PMID 22912387 DOI: 10.1158/1078-0432.Ccr-11-3260 |
0.451 |
|
| 2012 |
Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Current Treatment Options in Oncology. 13: 516-26. PMID 22833206 DOI: 10.1007/S11864-012-0204-6 |
0.504 |
|
| 2012 |
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Plos One. 7: e35309. PMID 22536370 DOI: 10.1371/Journal.Pone.0035309 |
0.413 |
|
| 2012 |
Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Science Translational Medicine. 4: 120ps2. PMID 22323827 DOI: 10.1126/Scitranslmed.3003728 |
0.442 |
|
| 2012 |
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, et al. ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 863-70. PMID 22215748 DOI: 10.1200/Jco.2011.35.6345 |
0.481 |
|
| 2012 |
Ohashi K, Sequist LV, Sos M, Chen X, Rudin CM, Moran T, Arcila ME, Lovly CM, Vnencak-Jones CL, Sasaki H, Dias-Santagata D, Dubinett SM, Riely GJ, Ladanyi M, Franklin WA, et al. Characteristics of NSCLCs harboring NRAS mutations. Journal of Clinical Oncology. 30: 7532-7532. DOI: 10.1200/Jco.2012.30.15_Suppl.7532 |
0.474 |
|
| 2012 |
Sewell A, Ogbeide E, Issaeva N, Lovly C, Boyd A, Gilbert J, Yarbrough WG. A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors Otolaryngology–Head and Neck Surgery. 147: P145-P145. DOI: 10.1177/0194599812451426A64 |
0.403 |
|
| 2011 |
Lovly CM, de Stanchina E, Chen H, Liang C, Pao W. Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13600. PMID 28023522 DOI: 10.1200/Jco.2011.29.15_Suppl.E13600 |
0.486 |
|
| 2011 |
Horn L, Chen H, Lovly CM, Andrews J, Yeh P, Levy MA, Pao W. DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7575. PMID 28023127 DOI: 10.1200/Jco.2011.29.15_Suppl.7575 |
0.474 |
|
| 2011 |
Levy MA, Lovly CM, Horn L, Naser R, Pao W. My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7576. PMID 28023120 DOI: 10.1200/Jco.2011.29.15_Suppl.7576 |
0.471 |
|
| 2011 |
Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7394-401. PMID 21948233 DOI: 10.1158/1078-0432.Ccr-11-1648 |
0.483 |
|
| 2011 |
Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research. 71: 4920-31. PMID 21613408 DOI: 10.1158/0008-5472.Can-10-3879 |
0.435 |
|
| 2011 |
Lovly CM, Carbone DP. Lung cancer in 2010: One size does not fit all. Nature Reviews. Clinical Oncology. 8: 68-70. PMID 21278771 DOI: 10.1038/Nrclinonc.2010.224 |
0.442 |
|
| 2011 |
Lovly CM, Li C, Hutchison AS, Carbone DP, Johnson DH, Keedy VL, Pao W, Sandler A, Horn L. A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). Journal of Clinical Oncology. 29: 7094-7094. DOI: 10.1200/Jco.2012.30.15_Suppl.7094 |
0.356 |
|
| 2011 |
Acquaviva J, Sang J, Sequeira M, Smith D, Zhang C, Lovly C, Wada Y, Blackman RK, Proia DA. Abstract 1638: Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancer Cancer Research. 71: 1638-1638. DOI: 10.1158/1538-7445.Am2011-1638 |
0.521 |
|
| 2010 |
Lovly CM, Stanchina Ed, Liang C, Pao W. Abstract 1788: Preclinical development of a selective, potent small molecule ALK inhibitor Cancer Research. 70: 1788-1788. DOI: 10.1158/1538-7445.Am10-1788 |
0.466 |
|
| 2008 |
Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Molecular and Cellular Biology. 28: 5874-85. PMID 18644861 DOI: 10.1128/Mcb.00821-08 |
0.578 |
|
| 2007 |
King JB, Gross J, Lovly CM, Piwnica-Worms H, Townsend RR. Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 21: 3443-51. PMID 17918214 DOI: 10.1002/Rcm.3223 |
0.525 |
|
| 2006 |
King JB, Gross J, Lovly CM, Rohrs H, Piwnica-Worms H, Townsend RR. Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Analytical Chemistry. 78: 2171-81. PMID 16579595 DOI: 10.1021/Ac051520L |
0.519 |
|
| 2003 |
Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Molecular Cancer Research : McR. 1: 598-609. PMID 12805407 |
0.642 |
|
| 2001 |
Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 20: 1839-51. PMID 11313932 DOI: 10.1038/Sj.Onc.1204259 |
0.528 |
|
| 1997 |
Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Molecular and Cellular Biology. 17: 2020-9. PMID 9121450 DOI: 10.1128/Mcb.17.4.2020 |
0.323 |
|
| Show low-probability matches. |